Corgenix Medical Corp announces increase in AspirinWorks test laboratories
Monday, January 28, 2008
Jan 28, 2008 (M2 EQUITYBITES via COMTEX) -- CONX | news | PowerRating | PR Charts -- Corgenix Medical Corporation (OTCBB:CONX), a developer and marketer of diagnostic test kits, said on 25 January that the number of laboratories offering its AspirinWorks test is expanding continuously in the US and internationally, with growth expected into 2008.
The product is now available to physicians and laboratories across the US, Europe, South America, Mexico, Israel and Japan.
According to the company, the AspirinWorks test measures the effect of aspirin on platelets through direct measurement of thromboxane production (aspirin's target).
The AspirinWorks Test Kit is reportedly an enzyme-linked immunoassay (ELISA) used to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.
The product received clearance in May 2007 from the U.S. Food and Drug Administration for in vitro diagnostic use in the US.
More Breaking News about CONX
Corgenix Medical Corp. Expands Distribution of AspirinWorks(R) Test
CONX: Dat in British Medical Journal Establishes Concept of "Aspirin Resistance"
Corgenix Medical Says New Study Further Establishes Concept of ''Aspirin Resistance'' |
